Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: Results from the INACTION P25 study.
De Nicolò A, Palermiti A, Dispinseri S, Marchetti G, Trunfio M, De Vivo E, D'Avolio A, Muscatello A, Gori A, Rusconi S, Bruzzesi E, Gabrieli A, Bernasconi DP, Bandera A, Nozza S, Calcagno A; INACTION (Italian Network of Acute HIV Infection) study group. De Nicolò A, et al. Among authors: calcagno a. Int J Antimicrob Agents. 2024 Aug;64(2):107200. doi: 10.1016/j.ijantimicag.2024.107200. Epub 2024 May 18. Int J Antimicrob Agents. 2024. PMID: 38768738 Free article. Clinical Trial.
Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
González de Requena D, Calcagno A, Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G. González de Requena D, et al. Among authors: calcagno a. AIDS. 2006 Oct 3;20(15):1977-9. doi: 10.1097/01.aids.0000247121.19951.fa. AIDS. 2006. PMID: 16988521
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. de Requena DG, et al. Among authors: calcagno a. Antimicrob Agents Chemother. 2008 Mar;52(3):1066-71. doi: 10.1128/AAC.01063-07. Epub 2007 Dec 26. Antimicrob Agents Chemother. 2008. PMID: 18160524 Free PMC article.
Raltegravir penetration in seminal plasma of healthy volunteers.
Calcagno A, Bonora S, D'Avolio A, Siccardi M, Simiele M, Chiesa M, Gonzalez de Requena D, Perri GD. Calcagno A, et al. Antimicrob Agents Chemother. 2010 Jun;54(6):2744-5. doi: 10.1128/AAC.00241-10. Epub 2010 Mar 22. Antimicrob Agents Chemother. 2010. PMID: 20308369 Free PMC article. Clinical Trial. No abstract available.
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.
Gonzalez de Requena D, Bonora S, Viganò O, Calcagno A, Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G. Gonzalez de Requena D, et al. Among authors: calcagno a. J Antimicrob Chemother. 2011 Jan;66(1):192-200. doi: 10.1093/jac/dkq384. Epub 2010 Oct 29. J Antimicrob Chemother. 2011. PMID: 21037251 Free article.
Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.
Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan WS, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. Siccardi M, et al. Among authors: calcagno a. Pharmacogenet Genomics. 2010 Dec;20(12):759-65. doi: 10.1097/FPC.0b013e3283402efb. Pharmacogenet Genomics. 2010. PMID: 21217360 Clinical Trial.
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Calcagno A, Nozza S, Bonora S, Castagna A, Gonzalez de Requena D, D'Avolio A, Lazzarin A, Di Perri G. Calcagno A, et al. J Antimicrob Chemother. 2011 Aug;66(8):1932-4. doi: 10.1093/jac/dkr219. Epub 2011 Jun 4. J Antimicrob Chemother. 2011. PMID: 21642649 No abstract available.
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.
Bonora S, Calcagno A, Cometto C, Fontana S, Aguilar D, D'Avolio A, Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A, Di Perri G. Bonora S, et al. Among authors: calcagno a. Infection. 2012 Feb;40(1):69-75. doi: 10.1007/s15010-011-0223-4. Epub 2011 Dec 2. Infection. 2012. PMID: 22135137 Clinical Trial.
427 results